Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19.

ABSTRACT:

Background

There have been over 200 million cases and 4.4 million deaths from COVID-19 worldwide. Despite the lack of robust evidence one potential treatment for COVID-19 associated severe hypoxaemia is inhaled pulmonary vasodilator (IPVD) therapy, using either nitric oxide (iNO) or prostaglandins. We describe the implementation of, and outcomes from, a protocol using IPVDs in a cohort of patients with severe COVID-19 associated respiratory failure receiving maximal conventional support.

Methods

Prospectively collected data from adult patients with SARS-CoV-2 admitted to the intensive care unit (ICU) at a large teaching hospital were analysed for the period 14^th March 2020 - 11^th February 2021. An IPVD was considered if the PaO₂/FiO₂

SUBMITTER: Matthews L 

PROVIDER: S-EPMC9353318 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature